Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A 2025 Bayesian network meta-analysis placed retatrutide in comparative context against mono-agonists and dual agonists for weight-loss outcomes in non-diabetic populations (PMID 40685589)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 Study
NAD+ is essential to mitochondrial energy production
J.AnstromK
Gould and Pazdro, 2019
The 2026 Peptide Reclassification This reclassification does NOT affect retatrutide
US$ 22.08
US$ 28.28
US$ 26.28
US$ 28.09
US$ 28.09
US$ 26.33
US$ 23.72
